Cardiometabolic risks of antidepressant and antipsychotic drugs, part 1: Proarrhythmic risks of antidepressant and antipsychotic drugs

Psychiatric Times

Volumn 28, Issue 4, 2011, Pages 50-55

  Victor R Vieweg, W ^a   Hasnain, Mehrul ^b   Wood, Mark A ^a   Fernandez, Antony ^a,c   Lesnefsky, Edward J ^a,c   Pandurangi, Ananda K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955746759     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. ;349:1498-1504.
2. Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374:620-627.
3. Sicouri S, Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf. 2008; 7:181-194. (Pubitemid 351447701)
4. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. JAm Coll Cardiol. 1992;20:1391-1396.
5. Postema PG, Wolpert C, Amin AS, et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm. 2009;6:1335-1341.
6. Yap YG, Behr ER, Camm AJ. Drug-induced Brugada syndrome. Europace. 2009;11:989-994.
7. Vieweg WV, Wood MA, Fernandez A, et al. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging. 2009;26:997-1012.
8. Vincent GM. Long QT syndrome. Cardiol Clin. 2000;18:309-325.
9. Patel U, Pavri BB. Short QT syndrome: a review. Cardiol Rev. 2009; 17:300-303.
10. Helfand M, Buckley Dl, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med. 2009; 151:496-507.
11. Frasure-Smith N, Lespérance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry. 2008;65:62-71.
12. Postema PG, De Jong JSSG, Van der Bilt IA, Wilde AA. Accurate electrocardiographic assessment of the QT interval: teach the tangent. Heart Rhythm. 2008;5:1015-1018.
13. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal." J Cardiovasc Electophysiol. 2006;17:333-336. (Pubitemid 43344951)
14. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920;7:353-370.
15. Viskin S, Rosovski U, Sands AJ, et al. Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. Heart Rhythm. 2005;2:569574.
16. Bednar MM, Harrigan EP, Anziano RJ, et al. The QT interval. Prog Cardiovasc Dis. 2001; 43(5 suppl 1):1 -45.
17. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118:1768-1775.
18. Vieweg WV, Hasnain M, Pandurangi AK, Lesnefsky EJ. Major depression and coronary artery disease. Arch Gen Psychiatry. 2010; 67:653.
19. Hasnain M, Vieweg WVR, Lesnefsky EJ, et al. Depression screening in patients with coronary heart disease: a critical evaluation of the AHA guidelines. J Psychosom Res. In press.
20. Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. 2000;343:1942-1950. (Pubitemid 32064789)
21. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606-613. (Pubitemid 32823891)
22. Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. 2007;298:1794-1796. (Pubitemid 47598448)
23. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131. (Pubitemid 47529346)
24. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009;119:4-14.
25. Hamer M, David Batty G, Seldenrijk A, Kivimaki M. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J. 2011;32:437-442.
26. Fernandez A, Bang SE, Srivathsan K, Vieweg WV. Cardiovascular side effects of newer antidepressants. Anadolu Kardiyol Derg. 2007; 7:305-309. (Pubitemid 47455140)
27. Vieweg WVR, Nicholson CS. Antidepressant drugs and the cardiovascular system. Med Update Psychiatrists. 1996;1:154-160.
28. Vieweg WVR. Antidepressant drug-induced blood pressure changes and their management. Med Update Psychiatrists. 1996;1:161164.
29. Mark TL, Joish VN, Hay JW, et al. Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry. 2011;19:211215.
30. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001;58:1161-1167. (Pubitemid 33121508)
31. Zarate CA Jr, Patel J. Sudden cardiac death and antipsychotic drugs: do we know enough? Arch Gen Psychiatry. 2001;58:11681171.
32. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death [published correction appears in N Engl J Med. 2009;361:1814].
33. N Engl J Med. 2009;360:225-235.
34. Su HM, Chiu HC, Lin TH, et al. Longitudinal study of the ageing trends in QT interval and dispersion in healthy elderly subjects. Age Ageing. 2006;35:636-638.
35. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requiremnts for Registration of Pharmaceuticals for Human Use E14 guidelines. J Clin Pharmacol. 2006;46:498-507.
36. Camm AJ, Malik M, Yap YG. Acquired Long QT Syndrome. London: Blackwell Futura; 2004.
37. Browne KF, Prystowsky E, Heger JJ, et al. Prolongation of the Q-T interval in man during sleep. Am J Cardiol. 1983;52:55-59. (Pubitemid 13061326)
38. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol. 1991;67:774-776.
39. Tutar HE, Ocal B, lmamogtu A, Atalay S. Dispersion of QT and QTc interval in healthy children, and effects of sinus arrhythmia on QT dispersion. Heart 1998;80:77-79. (Pubitemid 28351125)
40. Khan SP, Dahlvani S, Vieweg WVR, et al. Electrocardiographic QT interval in a geropsychiatric inpatient population: a preliminary study. Med Psychiatr. 1998;1:71 -74.
41. Compton SJ, Lux RL, Ramsey MR, et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation. 1996;94:1018-1022. (Pubitemid 26292855)
42. Hatta K, Takahashi T, Nakamura H, et al. Hypokalemia and agitation in acute psychotic patients. Psychiatry Res. 1999;86:85-88. (Pubitemid 29234432)
43. Hatta K, Takahashi T, Nakamura H, et al. Prolonged QT interval in acute psychotic patients. Psychiatry Res. 2000;94:279-285. (Pubitemid 30417618)
44. Drew BJ, Ackerman MJ, Funk M, et al American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, Council on Cardiovascular Nursing, and the American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation [published correction appears in Circulation. 2010;122:e440].
45. Circulation. 2010;121:10471060.
46. Johnson JN, Grifoni C, Bos JM, et al. Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. Eur Heart J. 2011 Feb 22; [Epub ahead of print].
47. Phoon CK. Mathematic validation of a shorthand rule for calculating QTc. Am J Cardiol. 1998;82:400-402.